VIATRIS INC
Viatris Inc (VTRS) is a global pharmaceuticals company formed to manufacture, market and distribute a broad range of medicines, including generics, established brands and biosimilars. With a market cap of about $12.11 billion, the group operates at scale across multiple regions and emphasises manufacturing reach, product diversification and cost efficiency. Investors should know Viatris competes in price-sensitive markets where patent expiries, regulatory approvals and pricing pressure can affect margins. Management has focused on integrating operations and improving cash flow, but the company faces execution, regulatory and competitive risks. As with any equities, returns can vary and capital is at risk; this summary is general educational information, not personal investment advice. Potential investors should review the company’s latest financials, regulatory filings and consider their own objectives and risk tolerance or consult a professional before making decisions.
Stock Performance Snapshot
Analyst Rating
Analysts recommend holding Viatris stock, with a target price slightly above its current value.
Financial Health
Viatris is generating solid revenue and cash flow, indicating good financial performance overall.
Dividend
Viatris Inc. offers a steady dividend yield of 4.29%, which is appealing for dividend-seeking investors. If you invested $1000 you would be paid $42.90 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
AbbVie
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
AMGEN INC
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
APELLIS PHARMACEUTICALS INC
Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune diseases.
Baskets Featuring VTRS
Navigating Pharma Price Controls
President Trump's ultimatum to major pharmaceutical firms to lower drug prices creates significant market uncertainty for brand-name drug makers. This situation could benefit companies that thrive on reducing healthcare costs, such as generic drug manufacturers and prescription discount platforms.
Published: August 4, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Global manufacturing reach
Viatris’s wide geographic footprint helps distribution and scale, though regional regulations and pricing can influence returns.
Generics and biosimilars
Exposure to generics and emerging biosimilars offers volume opportunities, but pricing competition and approval timelines are important to watch.
Operational focus
Management has emphasised integration and cash generation to improve resilience, yet execution and market dynamics can affect results.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.